Literature DB >> 3383986

Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin.

R Preiss1, V K Brovtsyn, N I Perevodchikova, M B Bychkov, H Hüller, L A Belova, P Michailov.   

Abstract

The kinetics of platinum in plasma and erythrocytes, and its renal excretion, have been examined in five patients with non-small cell carcinoma of the lung, after treatment with cisplatin 50 mg/m2 (Platidiame) and, three weeks later, a combination of 50 mg/m2 cisplatin and 40 mg/m2 methotrexate. The patients were given 0.9% saline 1 l 1 h prior to drug application. Plasma platinum elimination was biphasic with a short initial phase (t1/2 alpha 10-31 min) and a long beta-phase (t1/2 beta 65-91 h). With the exception of increased AUC values in all five patients 0-8 h after the injection, no significant change in the kinetics of platinum in plasma was found after coadministration of methotrexate. In four of the five patients renal platinum excretion was reduced in the first 6 h after administration of methotrexate. The renal clearance of platinum was 50% lower in those four patients 0-3 h after the injection. With the exception of one patient, no signs of nephrotoxicity were observed after combined drug administration. Other toxic effects were mild and showed no increase after the initial administration of methotrexate.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3383986     DOI: 10.1007/bf00614550

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man.

Authors:  E S Henderson; R H Adamson; V T Oliverio
Journal:  Cancer Res       Date:  1965-08       Impact factor: 12.701

2.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

4.  Inhibition of renal tubular transport of methotrexate by probenecid.

Authors:  R S Bourke; G Chheda; A Bremer; O Watanabe; D B Tower
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

5.  Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

Authors:  S Meijer; D T Sleijfer; N H Mulder; W J Sluiter; J Marrink; H S Koops; T M Brouwers; J Oldhoff; G K van der Hem; E Mandema
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

6.  A microcomputer program in Basic for iterative, non-linear data-fitting to pharmacokinetic functions.

Authors:  F Nielsen-Kudsk
Journal:  Int J Biomed Comput       Date:  1983-03

7.  Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.

Authors:  C Jacobs; C N Coleman; L Rich; K Hirst; M W Weiner
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

8.  Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion.

Authors:  Y Wang; E Lantin; W W Sutow
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327

9.  Effect of probenecid and N'-methylnicotinamide on renal handling of cis-dichlorodiammineplatinum-II in rats.

Authors:  N M Osman; C L Litterst
Journal:  Cancer Lett       Date:  1983-05       Impact factor: 8.679

Review 10.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

View more
  2 in total

1.  Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.

Authors:  J D Holding; W E Lindup; D A Bowdler; M Z Siodlak; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

Review 2.  Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Authors:  Przemysław Koźmiński; Paweł Krzysztof Halik; Raphael Chesori; Ewa Gniazdowska
Journal:  Int J Mol Sci       Date:  2020-05-14       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.